Toggle light / dark theme

Washington [US], March 5 (ANI): A team of researchers from Michigan State University’s College of Veterinary Medicine made a discovery that may have significance for therapeutic gene editing strategies, cancer diagnostics and therapies and other advancements in biotechnology. Kathy Meek, a professor in the College of Veterinary Medicine, and collaborators at Cambridge University and the National Institutes of Health have uncovered a previously unknown aspect of how DNA double-stranded breaks are repaired.

A large protein kinase called DNA-PK starts the DNA repair process; in their new report, two distinct DNA-PK protein complexes are characterized, each of which has a specific role in DNA repair that cannot be assumed by the other.

“It still gives me chills,” says Meek. “I don’t think anyone would have predicted this.”

The COVID-19 pandemic has focused attention on patterns of infectious disease spillover. Climate and land-use changes are predicted to increase the frequency of zoonotic spillover events, which have been the cause of most modern epidemics. Characterising historical trends in zoonotic spillover can provide insights into the expected frequency and severity of future epidemics, but historical epidemiological data remains largely fragmented and difficult to analyse. We utilised our extensive epidemiological database to analyse a specific subset of high-consequence zoonotic spillover events for trends in the annual frequency and severity of outbreaks. Our analysis, which excludes the ongoing SARS-CoV-2 pandemic, shows that the number of spillover events and reported deaths have been increasing by 4.98% (confidence interval [CI]95% [3.22%; 6.76%]) and 8.7% (CI 95% [4.06%; 13.62%]) annually, respectively. This trend can be altered by concerted global efforts to improve our capacity to prevent and contain outbreaks. Such efforts are needed to address this large and growing risk to global health.

The immune system is a complex network of cells with critical functions in health and disease. However, a comprehensive census of the cells comprising the immune system is lacking. Here, we estimated the abundance of the primary immune cell types throughout all tissues in the human body. We conducted a literature survey and integrated data from multiplexed imaging and methylome-based deconvolution. We also considered cellular mass to determine the distribution of immune cells in terms of both number and total mass. Our results indicate that the immune system of a reference 73 kg man consists of 1.8 × 1012 cells (95% CI 1.5–2.3 × 1012), weighing 1.2 kg (95% CI 0.8–1.9). Lymphocytes constitute 40% of the total number of immune cells and 15% of the mass and are mainly located in the lymph nodes and spleen. Neutrophils account for similar proportions of both the number and total mass of immune cells, with most neutrophils residing in the bone marrow. Macrophages, present in most tissues, account for 10% of immune cells but contribute nearly 50% of the total cellular mass due to their large size. The quantification of immune cells within the human body presented here can serve to understand the immune function better and facilitate quantitative modeling of this vital system.

Metabolites called nucleotides are the building blocks of DNA and can impact cancer’s sensitivity or resistance to chemotherapy and radiation in brain cancer. Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite, called GTP, controls responses to radiation and chemotherapy in an unexpected way.

“We learned that if you increase a cell’s GTP levels, it makes it really resistant to radiation or chemotherapy. Lowering GTP levels, the cell becomes much more sensitive,” said Daniel Wahl, M.D., Ph.D., associate professor of radiation oncology at Michigan Medicine and senior author of this paper.

Researchers have long known that levels of nucleotides like GTP control how fast DNA damage is repaired, which in turn controls sensitivity to therapies.

A study by the Global Antibiotic Research & Development Partnership and Innoviva Specialty Therapeutics found a single dose of a first-in-class oral antibiotic called zoliflodacin was as safe and effective as standard therapy for uncomplicated urogenital gonorrhea. NIAID contributed financial and scientific support to the development of zoliflodacin and applauds its non-governmental and private sector partners on successfully conducting the study. Read the NIH statement on these results: https://go.nih.gov/Wquuct


A single dose of a novel oral antibiotic called zoliflodacin has been found to be as safe and effective as standard therapy for uncomplicated urogenital gonorrhea in an international Phase 3 non-inferiority clinical trial, according to the Global Antibiotic Research & Development Partnership (GARDP), the study sponsor. Gonorrhea treatment options are increasingly limited due to antimicrobial resistance seen in Neisseria gonorrhoeae, the bacteria that cause gonococcal infection.

Because of the imperative to expand the gonococcal therapeutic pipeline, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has contributed financial and scientific support to the development of zoliflodacin and applauds its non-governmental and private sector partners on successfully conducting the Phase 3 study. This research has generated important new evidence for a field in urgent need of alternative therapeutic options. Specifically, zoliflodacin may offer an alternative to current therapy for uncomplicated urogenital gonococcal infection.

“Decades-old antibiotics are becoming ineffective for treating Neisseria gonorrhoeae, which creates a huge global health burden. NIAID celebrates this exemplary public-private partnership for supporting science to improve the sexual health of people worldwide,” said NIAID Director Jeanne Marrazzo, M.D. “These encouraging results should bolster additional, intersectoral efforts to develop safe and effective therapeutic options for gonorrhea and other bacteria that exhibit antimicrobial resistance.”

Researchers at the National Institutes of Health have developed a way to potentially increase the effectiveness of T cell–based immunotherapy treatments, such as CAR T-cell therapy, against solid tumors. T cells are specialized white blood cells of the immune system that eliminate infected or abnormal cells. In animal studies, the enhanced T-cell therapies were effective against cervical cancer and neuroblastoma, a common solid tumor in children. The findings, by scientists at the National Cancer Institute (NCI), part of NIH, appear in Clinical Cancer Research.

CAR T-cell therapy is a form of cellular immunotherapy that involves engineering T cells in the laboratory so they can specifically target and kill tumors. CAR T-cell therapy has been successful in treating blood cancers, but it hasn’t worked well for solid tumors. To improve the effectiveness of T-cell therapy against solid tumors, researchers at NCI’s Center for Cancer Research engineered T cells (CAR T cells and another form of cellular immunotherapy called TCR T cells) to carry cytokines, which are proteins that can boost T-cell function.

In laboratory studies, CAR and TCR T cells modified to express the cytokines IL-15 and IL-21 on their surface killed far more than T cells carrying just one of these cytokines or neither of them. Previous research has found that treating patients with large amounts of cytokines caused severe, potentially fatal, side effects. The new approach aims to deliver this cytokine boost in a much more targeted way.

The robot guide dog possesses the ability to respond to tugs on a leash.

Researchers have created a robot guide dog to make life easier for the visually impaired with its ability to respond to tugs on a leash. The team of engineers at Binghamton University’s Computer Science Department in New York State has been developing a robotic seeing-eye dog to improve accessibility for those who are visually impaired. Last year, they performed a trick-or-treating exercise with its quadruped robotic dog.

Now, they have demonstrated a robot dog leading a person down a lab hallway, confidently and carefully reacting to directive instructions. Engineers were surprised that throughout the visually impaired… More.


Stephen Folkerts ‘24.

Nanotechnology sounds like a futuristic development, but we already have it in the form of CPU manufacturing. More advanced nanotech could be used to create independent mobile entities like nanobots. One of the main challenges is selecting the right chemicals, elements, and structures that actually perform a desired task. Currently, we create more chemically oriented than computationally oriented nanobots, but we still have to deal with the quantum effects at tiny scale.

One of the most important applications of nanotechnology is to create nanomedicine, where the technology interacts with biology to help resolve problems. Of course, the nanobots have to be compatible with the body (e.g. no poisonous elements if they were broken down, etc).

We dive into an interesting study on creating nanobarrels to deliver a particular payload within the bloodstream (currently in animals, but eventually in humans). This study is able to deliver RNA to cancer cells that shuts them down, without affecting the rest of the body. This type of application is why the market for nanotechnology keeps growing and will have a substantial impact on medicine in the future.

#nanotech #nanobots #medicine.

Colorectal cancer screening is widely recommended for adults ages 45 to 75 with an average risk of developing the disease. However, many people don’t realize that the benefits of screening for this type of cancer aren’t always the same for older adults.

“While many clinicians simply follow guideline recommendations for colon screening in adults within this age range, this isn’t always the best approach,” said Sameer Saini, M.D., M.S., who is a gastroenterologist at both Michigan Medicine and the Lieutenant Colonel Charles S. Kettles VA Medical Center and is as a health services researcher at the University of Michigan Institute for Healthcare Policy and Innovation and the Ann Arbor VA Center for Clinical Management Research, or CCMR.

“As individuals get older, they often acquire health problems that can lead to potential harm when coupled with endoscopy. While guidelines recommend a personalized approach to screening in average risk individuals between ages 76 and 85, there are no such recommendations for older adults who are younger than age 76—individuals who we commonly see in our clinics.”

Google’s new technique works by sending low-intensity ultrasonic probing signals via the speakers.

Researchers at Google have devised a technology that allows active noise-canceling (ANC) wearables to feature health-sensing applications.

The team utilized a technique called audio plethysmography (APG) in ANC wearables to monitor a user’s physiological data, such as heart rate and heart rate variability, without the need for additional sensors or sacrificing battery life.